Q2 Earnings Estimate for Indivior Issued By HC Wainwright

Indivior PLC (NASDAQ:INDV) – HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Indivior in a research note issued on Monday, January 12th. HC Wainwright analyst B. Folkes expects that the company will earn $0.74 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $48.00 target price on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s Q3 2026 earnings at $0.75 EPS, Q4 2026 earnings at $0.79 EPS and FY2030 earnings at $3.77 EPS.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The business had revenue of $314.00 million for the quarter, compared to analysts’ expectations of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%.

A number of other research analysts have also commented on INDV. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Craig Hallum reaffirmed a “buy” rating and set a $41.00 price target on shares of Indivior in a research note on Friday, October 31st. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Morgan Stanley reissued an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a research note on Wednesday, December 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $41.00 target price (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $34.57.

Indivior Trading Down 1.1%

Indivior stock opened at $33.63 on Tuesday. Indivior has a 52 week low of $7.62 and a 52 week high of $38.00. The stock has a market cap of $4.20 billion, a price-to-earnings ratio of 36.55 and a beta of 0.75. The company’s 50-day moving average price is $34.30 and its two-hundred day moving average price is $26.39.

Insiders Place Their Bets

In other news, Director Mark Stejbach acquired 775 shares of Indivior stock in a transaction on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the purchase, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. This represents a 4.82% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Keith Humphreys bought 775 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director owned 5,802 shares of the company’s stock, valued at $205,332.78. This represents a 15.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 4,871 shares of company stock worth $172,385 over the last three months.

Hedge Funds Weigh In On Indivior

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oaktree Capital Management LP lifted its holdings in shares of Indivior by 2,241.6% in the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after purchasing an additional 246,776,273 shares in the last quarter. Two Seas Capital LP raised its position in Indivior by 0.4% during the second quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock valued at $168,151,000 after buying an additional 41,018 shares during the period. Goldman Sachs Group Inc. raised its position in Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after buying an additional 1,299,425 shares during the period. Rubric Capital Management LP lifted its stake in Indivior by 31.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after acquiring an additional 1,117,140 shares in the last quarter. Finally, Newtyn Management LLC boosted its position in Indivior by 61.1% during the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after acquiring an additional 1,592,982 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior News Roundup

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $48 price target, and published near‑term quarterly guidance (Q1 2026: $0.72 EPS; Q2: $0.74; Q3: $0.75; Q4: $0.79) plus longer‑run upside (FY2030: $3.77 EPS), which supports upside vs. current levels. MarketBeat: Indivior analyst note
• Positive Sentiment: Coverage summary shows the consensus analyst stance remains favorable — Indivior has an average “Buy” rating from analysts, reinforcing that the market still sees demand drivers and valuation upside. AmericanBankingNews: INDV Given Average Rating of “Buy”
• Neutral Sentiment: HC Wainwright published a full set of quarterly forecasts for 2026 that smooth expected quarterly earnings delivery across the year (Q1–Q4 estimates as above), providing more clarity on near‑term cash flow but not changing the immediate narrative. MarketBeat: Indivior quarterly estimates
• Negative Sentiment: HC Wainwright cut multi‑year EPS forecasts (FY2026: from $3.22 → $3.00; FY2027: $3.43 → $3.21; FY2028: $3.56 → $3.35; FY2029: $3.75 → $3.56), lowering longer‑term growth expectations and likely applying downward pressure to the share price. MarketBeat: Indivior EPS revisions

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.